Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Acta Neuropathol. 2021 Jun 21;142(4):629–642. doi: 10.1007/s00401-021-02330-2

Fig. 1.

Fig. 1

TDP-43 immunohistochemistry in anterior cingulate brain sections illustrate the spectrum of pathology (a-d). Each region assessed was assigned a semiquantitative score for TDP-43 pathology: 0 = none (a), 0.5 = rare, 1 = mild (b), 2 = moderate (c) or 3 = severe (d). “Rare” is defined as a mild level of TDP-43 pathology in a single field of view. Global TDP-43 pathology scores differ significantly among TMEM106B genotypes under a major (T)-allele dominant model in ALS (e) but not in FTLD-TDP (g). C9orf72 expansion significantly associates with the global extent of TDP-43 pathology in both ALS (f) and FTLD-TDP (h). Scale bar = 50 μm.